[Federal Register Volume 67, Number 250 (Monday, December 30, 2002)]
[Notices]
[Page 79575]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-32812]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Intent To Grant an Exclusive License of a U.S. Government-Owned 
Patent

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(I)(i), 
announcement is made of the intent to grant an exclusive, royalty-
bearing, revocable license to U.S. patent number 6,387,665 issued May 
14, 2002 entitled ``Method of Making a Vaccine for Anthrax,'' and U.S. 
patent number 6,316,006 issued November 13, 2001 entitled ``Asporogenic 
B. Anthracis Expression System'' to VaxGen, Inc. with its principal 
place of business at 1000 Marina Blvd., Suite 200, Brisbane, Ca 94005. 
The exclusive field of use will be in field of preventive vaccines 
against anthrax infection.

DATES: File written objections by January 14, 2003.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Anyone wishing to object to the grant of 
this license can file written objections along with supporting 
evidence, if any, within 15 days from the date of this publication. 
Written objections are to be filed with the Command Judge Advocate (see 
addresses).

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-32812 Filed 12-27-02; 8:45 am]
BILLING CODE 3710-08-M